Business
ProtoKinetix AAGP® Operational Update
ProtoKinetix AAGP® Operational Update.
About this update from Protokinetix, Inc.
[{"type":"text","content":"\nProtoKinetix, Incorporated (www.protokinetix.com) (the \"Company\" or \"ProtoKinetix\") (OTCQB:PKTX) is pleased to provide the following updates regarding upcoming news in key areas.\n\n\nCurrent projects updates are expected from the following:\n\n\n\n 1.\n\nDry Eye Disease (DED) – ProtoKinetix is expecting closure of agreements for the first steps in a roll-out of a new product line development that will test AAGP® for treatments related to Dry Eye Disease. An update is expected for the 3rd week of November.\n\n\n\n\n \n\n \n\n\n\n\n 2.\n\nRetinal Cell Replacement – Final phase of the work that was conducted by Dr. Kevin Gregory-Evans has been completed, the data is being compiled. An update is expected in December of this year.\n\n\n\n\n\nSocial Media:\n\n\nFor more Company information and to sign up for regular updates, visit our website at ProtoKinetix.com.\n\n\nPlease visit our new Facebook page: ProtoKinetix Facebook \nJoin us on Twitter @ProtoKinetix. \nJoin us on Linkedin: ProtoKinetix Linkedin \n\nOur new website is expected to be live in the first quarter of 2020.\n\n\nAbout ProtoKinetix, Incorporated\n\n\nProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP®) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing, the University of Alberta has begun Phase 1 human clinical trials. Additional studies will be expanded are planned to include whole organ transplantation and all therapies that are being developed globally to date; diabetes, retinal degeneration, cardiac repair and many other degenerative conditions. In addition, we are studying the potential impact on several cancer therapies.\n\n\nCautionary Note Regarding Forward-Looking Statements \n\n\nThe information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and b...